We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Nuformix Plc | LSE:NFX | London | Ordinary Share | GB00BYW79Y38 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.005 | -2.70% | 0.18 | 0.18 | 0.22 | 0.18 | 0.18 | 0.18 | 372,466 | 08:10:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -859k | -0.0012 | -1.50 | 1.34M |
From Apr 2019 to Apr 2024
TIDMNFX
RNS Number : 4909Y
Nuformix PLC
06 December 2017
Nuformix plc
("Nuformix" or "the Company")
Grant of Warrants at 6p per share
Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces that Warrants over new ordinary shares have been granted to Beaufort Securities Limited, and have vested in accordance with the terms agreed with its recent appointment as the Company's broker:
Hot Features
Premium
Warrants over no. Exercise price Lapse date
of shares per share
------------------ --------------- ------------
1,000,000 6 pence 20 November
2020
------------------ --------------- ------------
Follow Nuformix on Vox Markets: follow at www.voxmarkets.co.uk/company/NFX
and www.nuformix.com
Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.
ENDS
Enquiries:
Nuformix plc Dan Gooding, Chief Executive +44 (0)1223 Officer 423667 Beaufort Securities Limited (Joint Broker) +44 (0)20 7382 Jon Belliss 8300 Gable Communications Ltd +44 (0)20 7193 John Bick / Justine James 7463
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix' risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.
Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2008 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEEAAASESLXFAF
(END) Dow Jones Newswires
December 06, 2017 02:00 ET (07:00 GMT)
1 Year Nuformix Chart |
1 Month Nuformix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
